XOMA Royalty Completes Sale of Kinnate Pipeline Assets

Core Viewpoint - XOMA Royalty Corporation has successfully sold its remaining Kinnate pipeline assets for up to $270 million in upfront and milestone payments, along with royalties on future commercial sales [1][2] Group 1: Financial Details - The total potential financial benefit from the sale includes up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens [1] - Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related payments made to XOMA Royalty prior to April 2, 2029 [2] Group 2: Company Background - XOMA Royalty Corporation operates as a biotechnology royalty aggregator, acquiring future economic rights associated with therapeutic candidates licensed to pharmaceutical or biotechnology companies [3] - The company provides non-dilutive, non-recourse funding to sellers, enabling them to advance their internal drug candidates or for general corporate purposes [3] Group 3: Current Portfolio - As of the date of the press release, XOMA Royalty's milestone and royalty portfolio includes commercial assets such as VABYSMO®, OJEMDA™, MIPLYFFA™, XACIATO™, IXINITY®, and DSUVIA® [6]